Hangzhou Tigermed Consulting Co., Ltd. (HNGZY)
USD 4.14
(0.0%)
USD 4.14
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.18 Billion USD | 6.0% |
| 2022 | 3.94 Billion USD | 5.99% |
| 2021 | 3.72 Billion USD | 24.89% |
| 2020 | 2.98 Billion USD | 174.53% |
| 2019 | 1.08 Billion USD | -76.77% |
| 2018 | 4.67 Billion CNY | 30.55% |
| 2017 | 3.58 Billion CNY | 50.03% |
| 2016 | 2.38 Billion CNY | 48.34% |
| 2015 | 1.61 Billion CNY | 18.59% |
| 2014 | 1.35 Billion CNY | 68.02% |
| 2013 | 808.01 Million CNY | 10.26% |
| 2012 | 732.83 Million CNY | 292.4% |
| 2011 | 186.75 Million CNY | 55.75% |
| 2010 | 119.91 Million CNY | 77.94% |
| 2009 | 67.38 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 30.07 Billion CNY | 1.25% |
| 2024 Q3 | 30.27 Billion CNY | -0.55% |
| 2024 Q2 | 30.44 Billion CNY | 1.24% |
| 2023 Q4 | 29.68 Billion CNY | -1.3% |
| 2023 Q3 | 30.07 Billion CNY | 1.37% |
| 2023 FY | 4.18 Billion USD | 6.0% |
| 2023 Q1 | 4.09 Billion USD | 3.84% |
| 2023 Q2 | 29.66 Billion CNY | 623.64% |
| 2022 Q3 | 3.82 Billion USD | -85.11% |
| 2022 Q4 | 3.94 Billion USD | 3.16% |
| 2022 FY | 3.94 Billion USD | 5.99% |
| 2022 Q1 | 24.8 Billion CNY | 4.47% |
| 2022 Q2 | 25.7 Billion CNY | 3.63% |
| 2021 Q4 | 23.74 Billion CNY | 8.13% |
| 2021 FY | 3.72 Billion USD | 24.89% |
| 2021 Q1 | 3.09 Billion CNY | -84.14% |
| 2021 Q2 | 3.28 Billion CNY | 6.15% |
| 2021 Q3 | 21.95 Billion CNY | 568.5% |
| 2020 Q2 | 9.26 Billion CNY | 12.44% |
| 2020 Q3 | 18.82 Billion CNY | 103.18% |
| 2020 Q4 | 19.5 Billion CNY | 3.59% |
| 2020 FY | 2.98 Billion USD | 174.53% |
| 2020 Q1 | 8.24 Billion CNY | 8.91% |
| 2019 Q3 | 6.31 Billion CNY | -1.72% |
| 2019 Q2 | 6.42 Billion CNY | 45.8% |
| 2019 Q4 | 7.56 Billion CNY | 19.94% |
| 2019 Q1 | 4.4 Billion CNY | -5.87% |
| 2019 FY | 1.08 Billion USD | -76.77% |
| 2018 Q1 | 3.93 Billion CNY | 9.8% |
| 2018 Q3 | 4.07 Billion CNY | 3.09% |
| 2018 Q2 | 3.95 Billion CNY | 0.54% |
| 2018 Q4 | 4.67 Billion CNY | 14.72% |
| 2018 FY | 4.67 Billion CNY | 30.55% |
| 2017 Q3 | 3.38 Billion CNY | 4.54% |
| 2017 Q1 | 2.45 Billion CNY | 2.97% |
| 2017 FY | 3.58 Billion CNY | 50.03% |
| 2017 Q4 | 3.58 Billion CNY | 5.82% |
| 2017 Q2 | 3.23 Billion CNY | 31.71% |
| 2016 Q3 | 2.13 Billion CNY | -0.16% |
| 2016 FY | 2.38 Billion CNY | 48.34% |
| 2016 Q4 | 2.38 Billion CNY | 11.71% |
| 2016 Q2 | 2.14 Billion CNY | 3.67% |
| 2016 Q1 | 2.06 Billion CNY | 28.29% |
| 2015 FY | 1.61 Billion CNY | 18.59% |
| 2015 Q3 | 1.39 Billion CNY | 21.51% |
| 2015 Q4 | 1.61 Billion CNY | 15.39% |
| 2015 Q2 | 1.14 Billion CNY | -0.34% |
| 2015 Q1 | 1.15 Billion CNY | -15.13% |
| 2014 Q2 | 882.41 Million CNY | -0.19% |
| 2014 FY | 1.35 Billion CNY | 68.02% |
| 2014 Q1 | 884.09 Million CNY | 9.42% |
| 2014 Q4 | 1.35 Billion CNY | 12.8% |
| 2014 Q3 | 1.2 Billion CNY | 36.39% |
| 2013 Q3 | 753.07 Million CNY | 2.8% |
| 2013 Q4 | 808.01 Million CNY | 7.3% |
| 2013 FY | 808.01 Million CNY | 10.26% |
| 2013 Q1 | 752.42 Million CNY | 2.67% |
| 2013 Q2 | 732.57 Million CNY | -2.64% |
| 2012 Q3 | 708.54 Million CNY | 231.22% |
| 2012 FY | 732.83 Million CNY | 292.4% |
| 2012 Q2 | 213.91 Million CNY | 0.0% |
| 2012 Q4 | 732.83 Million CNY | 3.43% |
| 2011 Q4 | 186.75 Million CNY | 0.0% |
| 2011 FY | 186.75 Million CNY | 55.75% |
| 2010 FY | 119.91 Million CNY | 77.94% |
| 2009 FY | 67.38 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| American Bio Medica Corporation | 1.26 Million USD | -329685.365% |
| Arrayit Corporation | 1 Million USD | -418234.896% |
| Atlantic International Corp. | 4.43 Million USD | -94233.538% |
| Biocept, Inc. | 30.87 Million USD | -13455.457% |
| Bioqual, Inc. | 56.58 Million USD | -7295.535% |
| CardioGenics Holdings Inc | 231.93 Thousand USD | -1804297.963% |
| DermTech, Inc. | 121.93 Million USD | -3332.278% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| HTG Molecular Diagnostics, Inc. | 17.77 Million USD | -23440.654% |
| iMD Companies, Inc. | 190.13 Thousand USD | -2200932.036% |
| IDenta Corp. | 1.52 Million USD | -273557.536% |
| Interpace Biosciences, Inc. | 13.02 Million USD | -32040.206% |
| Integrative Health Technologies, Inc. | 8.25 Million USD | -50615.225% |
| InVitro International | 1.53 Million USD | -272713.376% |
| Lumos Diagnostics Holdings Limited | 26.83 Million USD | -15493.473% |
| Many Bright Ideas Technologies Inc. | 2312.00 USD | -181010984.905% |
| Medical Imaging Corp. | 4.19 Million USD | -99741.333% |
| NovelStem International Corp. | 2.25 Million USD | -185523.903% |
| Optigenex Inc. | 1.88 Million USD | -221527.837% |
| PharmChem, Inc. | 2.76 Million USD | -151224.788% |
| Proteome Sciences plc | 14.58 Million USD | -28591.669% |
| Response Genetics, Inc | 48.88 Million USD | -8461.035% |
| Rennova Health, Inc. | 20.57 Million USD | -20242.316% |
| RushNet, Inc. | 6.04 Million USD | -69100.579% |
| ScreenPro Security Inc. | 1.26 Million USD | -331683.123% |
| Stella Diagnostics Inc. | 472.42 Thousand USD | -885753.628% |
| StageZero Life Sciences Ltd. | 700.65 Thousand USD | -597197.415% |
| Todos Medical Ltd. | 15.26 Million USD | -27311.91% |